The cost and time of developing and bringing a drug to market is over $1.3 billion and often takes as long as 15 years, if not longer. Because of this, major pharmaceutical marketers continue to outsource stages of development, and over the years Kalorama Information has observed this process. In past editions of our outsourcing market studies, we found that outsourcing moved from “should” to “must.” for manufacturers. This trend has only continued in the past two years.
Contract Research Organizations (CROs) and other entities can expect growing demand for their services. The demand for new drugs remains unabated, but the cost and need to bring those drugs to market is ever-increasing and intensifying. A key cost driver is the large number of failures during the expensive clinical trial phases. Driven by pressures to reduce costs, companies are increasingly implementing outsourcing strategies to increase revenues through faster drug development. By decreasing their in-house facilities and staff, and outsourcing more of their R&D functions, pharmaceutical and biotechnology companies are reshaping the drug development services industry.
Kalorama Information’s Outsourcing in Drug Development: The Contract Research (Clinical Trial) Market is the third edition of this study of the drivers for outsourcing drug development, the companies involved in this market and the opportunity for revenues.
As part of its comprehensive coverage of this market, this report contains:
- A Detailed Introduction to the Clinical Trial Process
- Statistics of Drugs in Development by Phase
- Market Size and Forecasts for Outsourcing In Drug Development by Academic Medical Center (AMC), Contract Research Organizations and Others.
- Main Drivers for Outsourcing in Drug Development
- How CROs are Meeting the Challenge of Patient Recruitment
- Discussion of Industry and Regulatory Trends
Protocols Funded in FY2009 by Percent and Gender
- Global R&D Expenditures Outsourced by Percent 2003-2010
- Selected Pharmaceutical Company Acquisitions, 2009-2011
- Top Ten Therapeutic Categories in R&D
- Selected Acquisitions of Leading CROs
- Increasing role of EDCs
- Globalization Trends in Drug Development and Breakout of Clinical Trials by Region
- Directory of Companies
- Market Share of Major CROs 2011
- Profiles of CROs, Contract Laboratories, Clinical Trial Labs and EDC Solution Companies
As part of Kalorama Information’s research process, information for this report is gathered from sources including trade press, company reports and government databases. Kalorama Information’s analyst also interviewed dozens of experts in the industry to discover new trends and confirm assumptions.
As part of the report’s coverage , the following CROs, clinical trial laboratories, EDC companies and site management networks are profiled:
- Charles River Laboratories International, Inc.
- Covance, Inc.
- Encorium, Inc.
- Icon, PLC
- Parexel International Corporation
- Medical Marketing Services
- Pharmaceutical Product Development, Inc
- INC Research
- InVentiv Health
- Pra International
- Quintiles Transnational Corporation
- Radiant Development
- Theorem Clinical Research
- Bioanalytical Research Corporation
- Calvert Laboratories, Inc
- Crl Medinet
- Kronos Sicence Laboratories
- MedTox Scientific Inc.
- Pacific Biomarkers, Inc.
- PRL Central Laboratory Services
- Quest Diagnostics
- TGA Sciences, Inc.
- DaVita Clinical Research
- SMO-USA, Inc.
- CCBR-Synarc, Inc.
- Advanced Clinical Software
- eResearch Technology, Inc.
- Interactive Clinical Technologies, Inc.
- Medidata Solutions Worldwide
- Perceptive Informatics, Inc.
- EDC Solutions
- Pharsight Corporation
- Phase Forward, Inc.
All Kalorama reports advertise the single user price, which limits access to one user. We also feature department and global pricing for reports that will be utilized by more than one user at your company. Please ask your sales representative or select the correct license on our website.
For Kalorama’s take on the healthcare news of the week, based on our analysis of healthcare markets, follow Kalorama Information’s Key Point Blog at